Ezra Cohen to Molecular Targeted Therapy
This is a "connection" page, showing publications Ezra Cohen has written about Molecular Targeted Therapy.
Connection Strength
0.979
-
Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082.
Score: 0.171
-
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6.
Score: 0.115
-
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10; 33(29):3305-13.
Score: 0.114
-
Towards a personalized treatment of head and neck cancer. Am Soc Clin Oncol Educ Book. 2015; 28-32.
Score: 0.109
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469.
Score: 0.108
-
New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
Score: 0.090
-
Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46.
Score: 0.090
-
Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95.
Score: 0.089
-
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723.
Score: 0.032
-
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
Score: 0.031
-
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709.
Score: 0.030